William Jacot

Prognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohort

Stéphane Vignot, Youenn Drouet, Antonio Di Meglio, Anne‐Laure Martin et autres

BACKGROUND: Lymphopenia has been associated with poor outcomes in metastatic breast cancer (BC), but its prognostic relevance in early-stage disease remains unclear. This study aimed to evaluate the prognostic value of baseline lymphopenia in patients with non-metastatic BC using data from the …

fr (code pays fourni par la source)

Chemotherapy-induced gut microbiota taxonomic deviation and its association with outcomes and toxicities in breast cancer: CANTO microbiota.

Joana M. Ribeiro, Antonio Di Meglio, Marine Fidelle, Julie Havas et autres

2589 Background: Gut microbiota (GM) modulates immunotherapy (IT) efficacy and toxicity, but its impact on outcomes in breast cancer (BC) patients (pts) remains unclear. TOPOSCORE is a GM-derived score reflecting the ecosystem structure that classifies pts into SIG1+ or SIG2+ profiles, the …

fr (code pays fourni par la source)

Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.

Erika P. Hamilton, Giuseppe Curigliano, M Casado Martín, Florence Lerebours et autres

1005 Background: In the phase 3 HER2CLIMB-05 study (NCT05132582), TUC + maintenance HP demonstrated a statistically significant improvement in progression-free survival (PFS) vs control treatment (Tx) (hazard ratio: 0.641, P < 0.0001) in patients (pts) with HER2+ locally advanced or metastatic breast …

us, it, es, fr, jp, ca, cn, pe, gb, tw, kr, de (code pays fourni par la source)

Untargeted baseline metabolomic profiling to identify candidate markers of long-term severe cancer-related fatigue (CRF) in breast cancer (BC) survivors.

Antonio Di Meglio, Jérémie Jacquemin, Julie Havas, Anne-Laure Martin et autres

12118 Background: CRF is common and debilitating among BC survivors; however its predictors and underlying biology remain partially defined. We sought to identify baseline plasma metabolomic markers of subsequent CRF to inform risk prediction and symptom mechanisms. Methods: Baseline (pre-treatment [tx]) plasma …

fr (code pays fourni par la source)

Success rate in generating patient-derived xenograft (PDX) breast cancer models is associated with higher M2-polarized tumor-associated macrophage infiltration in the donor-tissue

L Jahn, B Orsetti, J Veh, C M Wild et autres

Objective: Patient-derived xenograft (PDX) breast cancer (BC) models are composed of implanted human BC tissue in athymic mice. Such PDX-models can be used to study tumor biology in vivo or for preclinical drug-development. M2-polarized tumor-associated macrophages (M2-TAMs) are involved in immunosuppression and …

de, fr (code pays fourni par la source)

438P Efficacity of tucatinib with trastuzumab (T) and pertuzumab (P) as maintenance therapy after local treatment of isolated brain progression for patient with HER2-positive metastatic breast cancer (mBC): InTTercePT UCBG-GINECO study

T. Bachelot, C Schiffler, B. Verret, I. Desmoulins et autres

More than 10% of HER2-positive mBC patients (pts) develop isolated central nervous system (CNS) metastases as initial site of progression when receiving first-line T+P. Currently, there is no evidence that modifying systemic treatment after local treatment could improve outcome. Tucatinib is an …

fr (code pays fourni par la source)

70P Modulation of the prognostic role of stromal tumor-infiltrating-lymphocytes by tumor proliferation in triple-negative breast cancer: Results from the European GAMBIT network

M.V. Dieci, D. Massa, E. Gasparini, S.O. Giacchetti et autres

Stromal tumor-infiltrating lymphocytes (sTILs) are associated with higher rates of pathological complete response (pCR) to neoadjuvant therapy (NAT) and improved survival in triple-negative breast cancer (TNBC). Tumor proliferation is linked to higher pCR rates but poorer survival. Whether tumor proliferation modifies the …

it, fr, nl (code pays fourni par la source)

517P Characteristics of long-term responders to first-line palbociclib in HR+/HER2- metastatic breast cancer: Results from the French ESME cohort

T. Grinda, P. Macouillard, T. Bachelot, V. Massard et autres

fr (code pays fourni par la source)

244p Pathological complete response to pembrolizumab in real-world TNBC: Subgroup analysis from the French early access program

A.T. De Nonneville, J-S. Frenel, D. Loirat, S. Mervoyer Becourt et autres

fr (code pays fourni par la source)

444P Long-term outcomes of isolated single breast cancer brain metastasis treated with neurosurgical resection: A multicentre retrospective study

G. Griguolo, M. Bottosso, L. Visani, I. Ratosa et autres

it, si, fr (code pays fourni par la source)

446P Real-world outcomes in patients with advanced breast cancer according to endocrine sensitivity/resistance definitions: A multicenter retrospective study from the ESME cohort

S. Cavaillon, E. Teruel, T. Grinda, Veronique C. Dieras et autres

Current definitions of endocrine sensitivity in advanced breast cancer (ABC) are based on expert consensus. We evaluated patient outcomes according to the ABC6/7 and ABC5 criteria, compared their prognostic performance and explored alternative thresholds.

fr (code pays fourni par la source)

459P Leptomeningeal disease in metastatic breast cancer: Incidence, prognosis, and treatment outcomes from ESME-MBC real-world cohort

F. Nouvel, M. Carton, L. Larrouquere, F. Le Du et autres

fr (code pays fourni par la source)